Phibro Animal Health (NASDAQ:PAHC) Upgraded to “Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also recently issued reports on PAHC. Morgan Stanley lifted their target price on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Barclays upped their target price on Phibro Animal Health from $20.00 to $22.00 and gave the company an “underweight” rating in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and an average target price of $21.00.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $21.25 on Friday. The firm has a market capitalization of $860.69 million, a price-to-earnings ratio of 44.27, a price-to-earnings-growth ratio of 0.45 and a beta of 0.58. The company has a debt-to-equity ratio of 2.99, a current ratio of 3.20 and a quick ratio of 1.37. The business’s 50 day simple moving average is $22.57 and its 200-day simple moving average is $22.59. Phibro Animal Health has a 12 month low of $12.05 and a 12 month high of $26.55.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, February 5th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. As a group, equities analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in PAHC. Point72 Asia Singapore Pte. Ltd. purchased a new position in Phibro Animal Health during the fourth quarter worth about $29,000. Lazard Asset Management LLC boosted its holdings in shares of Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company’s stock valued at $34,000 after purchasing an additional 1,589 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Phibro Animal Health in the 4th quarter valued at $69,000. Virtus Fund Advisers LLC purchased a new stake in shares of Phibro Animal Health during the 4th quarter valued at $69,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth $70,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.